Gastric cancer is one of the most malignant
tumor types, and its
metastasis is a notable cause of mortality. Among the methods of
tumor metastasis,
lymphatic metastasis is the predominant one in
gastric cancer. A previous study reported that the plasma oxidized low‑density lipoprotein (
oxLDL) is the risk factor associated with the development of
tumors in patients with abnormal lipid metabolism, but the influence of plasma
oxLDL in the
lymphatic metastasis of
gastric cancer remains unclear. In the present study, the concentration of plasma
oxLDL from patients with
gastric cancer was detected with an ELISA kit, and the lymphatic vessel density in
gastric cancer tissues was determined by D2‑40 staining. The correlation analysis of
oxLDL concentration and lymphatic vessel density demonstrated that plasma
oxLDL was positively correlated with
lymphatic metastasis in patients with
gastric cancer. Subsequently, the popliteal
lymph node metastasis animal experiment with nude mice confirmed that
oxLDL could promote the
lymphatic metastasis of
gastric cancer. Following this, the western blotting and ELISA data demonstrated that
oxLDL promoted the expression and secretion of vascular endothelia
growth factor (
VEGF)‑C in
gastric cancer cell lines. Finally, blocking the lectin‑like oxLDL‑1 (LOX‑1) receptor, a specific receptor for
oxLDL, and the nuclear factor (NF)‑κB signaling pathway following
oxLDL (50 µg/ml) treatment in HGC‑27 cells revealed that
oxLDL could activate the NF‑κB signaling pathway mediated by LOX‑1, with subsequent upregulation of VEGF‑C expression, and secretion in and from
gastric cancer cells, and finally that it could promote the
lymphatic metastasis of
gastric cancer. These data indicate the association between the plasma
oxLDL and the
lymphatic metastasis of
gastric cancer, and indicate that
oxLDL elimination may be a potential therapeutic target for the prevention and intervention of early
lymph node metastasis in
gastric cancer.